Regarding Daybue not a lot of new information.
- New hire for General Manager European Launch "very experienced in rare disease"
- Expanded salesforce should see impact in second half of this year (target new patients outside of CoE)
- 65% of active patients have been on drug longer than 1 year - as a result discontinuations seems to be reducing as per last earnings update.
A lot of information about their pipeline. Didn't hear anything about NNZ-2591 but it's rather dry content so I may have missed something.
Regarding Daybue not a lot of new information. New hire for...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |